Proxima (formerly VantAI) closed an $80 million oversubscribed seed round to develop AI‑designed proximity‑modulating drugs that rewire protein interactions. Led by DCVC with participation from Roivant and others, the New‑York‑based company will deploy proteome‑scale structural data and frontier AI models to discover therapies across cancer, immunology and other indications. CEO Zachary Carpenter framed the raise as building the foundation to scale next‑generation proximity therapeutics, pointing to partnerships already formed with Halda, Blueprint and Bristol Myers Squibb. For biotech strategists, the financing signals investor confidence in AI‑native discovery companies that aim to address historically intractable protein‑protein interaction targets.